[go: up one dir, main page]

DE69924284D1 - Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten - Google Patents

Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten

Info

Publication number
DE69924284D1
DE69924284D1 DE69924284T DE69924284T DE69924284D1 DE 69924284 D1 DE69924284 D1 DE 69924284D1 DE 69924284 T DE69924284 T DE 69924284T DE 69924284 T DE69924284 T DE 69924284T DE 69924284 D1 DE69924284 D1 DE 69924284D1
Authority
DE
Germany
Prior art keywords
neurodeegenerative
stimulators
treatment
neurotrophic factors
ophthalmic diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69924284T
Other languages
English (en)
Other versions
DE69924284T2 (de
Inventor
Iok-Hou Pang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Research LLC
Original Assignee
Alcon Manufacturing Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Manufacturing Ltd filed Critical Alcon Manufacturing Ltd
Application granted granted Critical
Publication of DE69924284D1 publication Critical patent/DE69924284D1/de
Publication of DE69924284T2 publication Critical patent/DE69924284T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
DE69924284T 1998-12-03 1999-12-01 Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten Expired - Lifetime DE69924284T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11098398P 1998-12-03 1998-12-03
US110983P 1998-12-03
PCT/US1999/028385 WO2000032197A1 (en) 1998-12-03 1999-12-01 Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases

Publications (2)

Publication Number Publication Date
DE69924284D1 true DE69924284D1 (de) 2005-04-21
DE69924284T2 DE69924284T2 (de) 2005-08-04

Family

ID=22335984

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69924284T Expired - Lifetime DE69924284T2 (de) 1998-12-03 1999-12-01 Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten

Country Status (16)

Country Link
EP (1) EP1135134B1 (de)
JP (1) JP2002531405A (de)
KR (1) KR100688137B1 (de)
CN (1) CN1325308A (de)
AR (1) AR022685A1 (de)
AT (1) ATE290866T1 (de)
AU (1) AU769290B2 (de)
BR (1) BR9915803A (de)
CA (1) CA2353527C (de)
DE (1) DE69924284T2 (de)
ES (1) ES2237196T3 (de)
HK (1) HK1038510B (de)
PT (1) PT1135134E (de)
TW (1) TWI246421B (de)
WO (1) WO2000032197A1 (de)
ZA (1) ZA200102714B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002004448A2 (en) * 2000-07-07 2002-01-17 Neotherapeutics, Inc. Methods for treatment of drug-induced peripheral neuropathy and related conditions
US20020156277A1 (en) * 2001-04-20 2002-10-24 Fick David B. Synthesis and methods of use of purine analogues and derivatives
EP1420791A4 (de) * 2001-08-29 2004-09-15 Alcon Inc Verwendung von verbindungen zur behandlung von erkrankungen infolge von verletzungen des hornhautnervs nach lasik- und anderen augenoperationen oder trauma
EP1666068A4 (de) * 2003-09-24 2010-08-04 Santen Pharmaceutical Co Ltd Mittel zur behandlung von augenerkrankungen mit verletzungen des sehnervs
CA2589001A1 (en) * 2004-11-19 2006-05-26 Kissei Pharmaceutical Co., Ltd. Preventive or therapeutic agent for neuropathic pain
EP1754474A1 (de) * 2005-02-02 2007-02-21 Eucro European Contract Research GmbH & Co. KG Verwendung von S-Clenbuterol
EP1859795A4 (de) 2005-03-15 2008-06-04 Ono Pharmaceutical Co Therapeutisches mittel für ophthalmische erkrankungen
DK2605769T3 (en) 2010-08-16 2016-10-24 Santhera Pharmaceuticals (Schweiz) Ag Benzoquinonderivater for the treatment of mitochondrial diseases of the eye
ES2841993T3 (es) * 2012-10-23 2021-07-12 Nicox Sa Compuestos donantes de óxido nítrico a base de quinona para uso oftálmico

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH059114A (ja) * 1990-08-29 1993-01-19 Takeda Chem Ind Ltd 糖尿病性合併症の予防・治療剤
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
KR100514277B1 (ko) * 1996-09-13 2005-09-13 유겐가이샤 사이센딴이가꾸겡꾸쇼 신경 영양 인자의 안과용 조성물, 시신경 기능 장애 치료제 및 시신경 기능 장애 치료 방법
AU4582797A (en) * 1996-09-13 1998-04-02 Regents Of The University Of California, The Methods for treatment of retinal diseases
JPH10218787A (ja) * 1997-02-06 1998-08-18 Akio Okamoto 神経栄養因子による眼科用組成物

Also Published As

Publication number Publication date
ATE290866T1 (de) 2005-04-15
JP2002531405A (ja) 2002-09-24
EP1135134A1 (de) 2001-09-26
WO2000032197A1 (en) 2000-06-08
CN1325308A (zh) 2001-12-05
AU769290B2 (en) 2004-01-22
CA2353527C (en) 2007-11-06
DE69924284T2 (de) 2005-08-04
EP1135134B1 (de) 2005-03-16
ZA200102714B (en) 2002-06-03
ES2237196T3 (es) 2005-07-16
AU3106600A (en) 2000-06-19
TWI246421B (en) 2006-01-01
AR022685A1 (es) 2002-09-04
BR9915803A (pt) 2001-08-21
KR20010075055A (ko) 2001-08-09
CA2353527A1 (en) 2000-06-08
HK1038510A1 (en) 2002-03-22
HK1038510B (zh) 2005-05-20
PT1135134E (pt) 2005-05-31
KR100688137B1 (ko) 2007-03-09

Similar Documents

Publication Publication Date Title
DE69936335D1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
ATE271038T1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
DE69724016D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
ATE417602T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE69903543D1 (de) Formulierungen zur behandlung von magen-speiseröhren reflux
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
DE60325770D1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
DE69824576D1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
DE69943089D1 (de) Methode zur behandlung von staphylokokkeninfektionen
DE69807466D1 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
DE69924284D1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE59704933D1 (de) Verwendung von PHMB zur Behandlung von Tumorerkrankungen
DE60018200D1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
ATE433323T1 (de) Verwendung von erythropoietin zur behandlung von primärer hämochromatosen
DE50212649D1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
ATE285764T1 (de) Rivastigmine zur behandlung von augenerkrankungen
ATE251167T1 (de) Oxazinocarbazole zur behandlung von cns- erkrankungen
ATE218866T1 (de) Kombinationstherapie zur behandlung von aids

Legal Events

Date Code Title Description
8364 No opposition during term of opposition